SGNT Related
-
Form 4 Sagent Pharmaceuticals, For: May 13 Filed by: FLANAGAN ROBERT J
-
Semi-Annual Changes to the NASDAQ Biotechnology Index
-
Sagent Pharmaceuticals (SGNT) Guidance Conservative - Jefferies
-
Form 10-Q Sagent Pharmaceuticals, For: Mar 31
-
Form 8-K Sagent Pharmaceuticals, For: Apr 30
-
Sagent Pharmaceuticals, Inc. (SGNT) Tops Q1 EPS Views; Guides FY13 Revs
-
Sagent Pharma (SGNT) to Acquire Remaining Interest in Chengdu
-
Sagent Pharmaceuticals Announces Agreement to Acquire Remaining 50% Interest in Chinese Manufacturing Joint Venture
-
Sagent Pharmaceuticals Reports First Quarter 2013 Financial Results
-
Sagent Pharmaceuticals Sets Date and Time for Release of First Quarter 2013 Financial Results
-
Leading Software Industry Executive, Andre M Boisvert, Joins Actian Corporation Board of Directors
-
Form 4 Sagent Pharmaceuticals, For: Mar 25 Filed by: HUSSEY JAMES M
-
Sagent Pharmaceuticals (SGNT) Amends Agreement with Actavis
-
Piper Jaffray Upgrades Sagent Pharmaceuticals (SGNT) to Overweight
-
Sagent Pharmaceuticals (SGNT) Tops Q4 EPS by 20c, Provides Outlook
-
Sagent Pharma (SGNT) Reports Temp. Import of Sodium Bicarbonate
-
Sagent (SGNT) Launches Flumazenil Injection
-
Sagent Pharma (SGNT) Files 24.05M Common SHelf for Shareholders
-
Sagent (SGNT) Launches Nafcillin for Injection
-
Sagent Pharmaceuticals, Inc. (SGNT) Tops Q3 EPS by 7c, Guides FY
-
Sagent Pharma (SGNT) Launches Caffeine Citrate Injection
-
Sagent Pharma (SGNT) Launches Vancomycin Hydrochloride for Injection
-
Guggenheim Starts Sagent Pharmaceuticals (SGNT) at Neutral
-
Needham & Company Maintains a 'Buy' on Sagent Pharmaceuticals (SGNT); Getting Some Mojo Back
-
Jefferies Maintains a 'Buy' on Sagent Pharmaceuticals (SGNT); Q2 Bottoms Out; Q3 Rebound with Leuco
-
Morgan Stanley Downgrades Sagent Pharmaceuticals (SGNT) to Equalweight
-
Bittersweet Comments from Needham & Co. regarding Sagent Pharmaceuticals (SGNT)
-
RBC Capital Downgrades Sagent Pharmaceuticals (SGNT) to Sector Perform
-
Notable 52-Week Highs and Lows of the Day 08/09: (PHM) (PPHM) (AEP) High; (THS) (SGNT) Low
-
Morning Movers 08/09: (RBN) (IL) (SGI) Higher; (DRL) (MITL) (WIFI) Lower
-
Sagent Pharmaceuticals, Inc. (SGNT) Tops Q2 EPS by 7c; Cuts FY12 Sales Outlook
-
Sagent Pharmaceuticals, Inc. (SGNT) halted, news pending
-
Trading Radar for 08/09: NVIDIA (NVDA), James River Coal (JRCC), Fusion-io (FIO), Lionsgate (LGF), Red Robin (RRGB) Report
-
Sagent Pharmaceuticals (SGNT) Launches Oxacillin for Injection
-
Needham & Company Upgrades Sagent Pharmaceuticals (SGNT) to Buy; Compelling Re-Entry Ahead of Expected 2H Growth
-
Needham & Company Maintains a 'Hold' on Sagent Pharmaceuticals (SGNT); Results On the Short Side of Expectations
-
Sagent Pharmaceuticals, Inc. (SGNT) Misses Q1 EPS by 2c
-
Trading Radar for 05/10: Kohls (KSS), Dynegy (DYN), Express Scripts (ESRX), Molycorp (MCP) Report
-
Piper Jaffray Starts Sagent Pharmaceuticals (SGNT) at Neutral
-
Piper Jaffray Starts Sagent Pharmaceuticals (SGNT) at Neutral
-
Auriga Starts Sagent Pharmaceuticals (SGNT) at Buy
-
Needham & Company Maintains a 'Hold' on Sagent Pharmaceuticals (SGNT); Impressive Q4, But Shares Fairly Valued
-
Sagent Pharmaceuticals, Inc. (SGNT) Reports Q4 Loss of $0.33, Offers FY12 Sales Guidance
-
Trading Radar for 02/16: GM (GM), Baidu.com (BIDU), Altria (MO), Orbitz (OWW), Sunpower (SPWR) Report
-
Capstone Investments Starts Sagent Pharmaceuticals (SGNT) at Buy
-
Collins Stewart Starts Sagent Pharmaceuticals (SGNT) at Buy; Potential Earnings Upside is Underappreciated
-
Sagent Pharmaceuticals, Inc. (SGNT) Posts Q3 Loss of $0.17, Sales Top Expectations
-
Trading Radar for 11/07: DISH Network (DISH), Sysco (SYY), EnerNOC (ENOC), Priceline.com (PCLN) Report
-
Sagent Pharmaceuticals (SGNT) To Benefit From Obama's Executive Order - Jefferies
-
JPMorgan Starts Sagent Pharmaceuticals (SGNT) at Neutral
Back to SGNT Stock Lookup
